[external] Personal MarketWatch: Briefing.com's Green dislikes Genentech, Celgene Aug 25, 2005
Personal MarketWatch: Briefing. com's Green dislikes Genentech, Celgene - Biotechnology - Entertainment and Leisure - Food - Gas/Utilities - Health-Care - Oil and Gas - Pharmaceuticals - Technology, Hardware and Equipment - Technology, Software - Telecommunications - Media - Food ages - Energy - Computer Hardware - Software - Fiber Optics - General - Markets/Exchanges - Market News. (Yahoo Finance -- Biotechnology & Drugs)
Novel Contrast Agent MS-325 Recommended for Approval in Europe Jun 27, 2005
Company: EPIX Medical Inc. Company: Schering Ag. (CBS MarketWatch - Press Releases)
Investor Notice: Murray, Frank & Sailer LLP Files Shareholder Class Action Against EPIX Pharmaceuticals, Inc. -- EPIX Feb 19, 2005
NEW YORK, Feb. 18, 2005 (PRIMEZONE) -- Murray, Frank & Sailer LLP announces that it has filed a class action lawsuit in the United States District Court for the District of Massachusetts on behalf of purchasers of the securities of EPIX Pharmaceuticals, Inc. (f/k/a EPIX Medical, Inc.) (``EPIX'' or the ``Company'') (NasdaqNM: - ) between July 10, 2003 and January 14, 2005, inclusive (the ``Class Period''). ADVERTISEMENT. (Primezone Releases)
Spector, Roseman & Kodroff, P.C. Announces The Filing of A Class Action Suit Against EPIX Pharmaceuticals, Inc. Feb 10, 2005
PHILADELPHIA, Feb. 9 /PRNewswire/ -- The law firm of Spector, Roseman ff, P.C. announces that it filed a securities class action lawsuit in the United States District Court for the District Court of Massachusetts, on behalf of purchasers of the common stock of EPIX Pharmaceuticals, Inc. (f/k/a EPIX Medical, Inc.) (collectively referred to as "EPIX" or the "Company") (Nasdaq: ) between July 10, 2003 through January 14, 2005, inclusive (the "Class Period"). The Complaint alleges that defendants... (PR Newswire)
Shareholder Class Action Filed Against EPIX Pharmaceuticals, Inc. (f/k/a EPIX Medical, Inc.) By The Law Firm of Schiffrin & Barroway, LLP Feb 2, 2005
Shareholder Class Action Filed Against EPIX Pharmaceuticals, Inc. (f/k/a EPIX Medical, Inc.) By The Law Firm of Schiffrin way, LLP ... Shareholder Class Action Filed Against EPIX Pharmaceuticals, Inc. (f/k/a EPIX Medical, Inc.) By The Law Firm of Schiffrin way, LLP ... Feb. 1 /PRNewswire/ -- The following statement was issued today by the law firm of Schiffrin way, LLP: Notice is hereby given that a class action lawsuit was filed in the United States District Court for the District of... (PR Newswire)
[external] Epix Imaging Agent Delayed Jan 15, 2005
Shares in drugmakers Epix Medical (nasdaq: - - ) and Schering AG (nyse: - - ) dropped 27% and 1. 5% respectively. (Yahoo Finance -- Major Drugs)
[external] Epix Pharma plunges on FDA setback Jan 15, 2005
Epix Pharma plunges on FDA setback - Biotechnology - Company Announcements. 1/15/2005 3:01:00 AM. (Yahoo Finance -- Biotechnology & Drugs)
[external] Schering-Plough takes hit on rating Jan 15, 2005
Biotech Stocks: Schering-Plough takes hit on rating - Biotechnology - General. 1/15/2005 3:01:00 AM. (Yahoo Finance -- Biotechnology & Drugs)
[external] Epix gets FDA extension, shares fall after hours Oct 5, 2004
Epix gets FDA extension, shares fall after hours. 10/5/2004 3:58:00 AM. (Yahoo Finance -- Biotechnology & Drugs)
WED Aug 11, 04, 4:56 PM Aug 12, 2004
" The 2004 Technology Fast 50 winner alphabetical listing is as follows: Akamai Technologies, Inc. American Tower Corporation Apogee Technology, Inc ArQule, Inc. Biogen Idec Inc BioSphere Medical, Inc. BuyerZone.com Centra Software, Inc. Charles River Development Color Kinetics Inc Connected Corporation Courion Corporation Crunch Time! Information Systems Curis, Inc. Cytyc Corporation Datafarm, Inc. Dyax Corp. eCopy, Inc. edocs, Inc. Ektron, Inc. EPIX Medical, Inc. Evergreen Solar, Inc.... (PR Newswire)
Stocks to watch Thursday: INTC, FNSR, STX, ULTE, MBG Jun 3, 2004
EPIX Medical () slid more than 5 percent after the magnetic resonance imaging pharmaceutical company said late Tuesday that it was privately-selling up to $75 million worth of debt, convertible into common stock. The company said it planned to grant initial debt buyers options to buy up to an additional $25 million worth of the debt. (Investor's Business Daily)
EPIX Announces Pricing of $75 Million of 3% Convertible Senior ... Jun 2, 2004
--(BUSINESS WIRE)--June 2, 2004--EPIX Medical, Inc., (the "Company") (Nasdaq: EPIX), a developer of specialty pharmaceuticals for magnetic resonance imaging (MRI), announced today the pricing of its offering of $75 million of convertible senior notes due 2024 to be sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act") ... EPIX Medical, Inc.Peyton Marshall or Angela Elrod, 617-250-6012. (Business Wire, CA)
Your Portfolio Jun 2, 2004
USATODAY.com - Goal: Find new job, but don't deplete all savings. Posted 5/31/2004 9:17 PM Updated 5/31/2004 11:42 PM. (USA Today -- Money)
EPIX Medical Files NDA For Its Blood-Pool Agent MS-325 Dec 16, 2003
EPIX Medical Inc. filed its first new drug application along with partner, Schering AG, for a blood-pool agent called MS-325 for vascular imaging with magnetic resonance angiography. Reaching the regulatory filing phase is particularly exciting for EPIX, the Cambridge, Mass (BioWorld Online (subscription)
Schering files for US nod for contrast agent Dec 16, 2003
FRANKFURT, Dec 16 (Reuters) - German drugs group Schering AG said on Tuesday its new contrast agent MS-325 had been submitted for marketing approval in the United States by its partner, U.S.-based Epix Medical Inc (nasdaq: EPIX - news - people). The agent is used in Magnetic Resonance Angiography (MRA), a method which scans blood vessels without the need for X-rays and can be used to diagnose heart disorders, strokes and blood-vessel diseases (Forbes)
More Bay State firms to join the Nasdaq Biotech Index Nov 14, 2003
Indevus Pharmaceuticals Inc. of Lexington and Epix Medical Inc. in Cambridge have been selected for addition to the Nasdaq Biotechnology Index beginning Nov. 24. Launched in 1993, the Nasdaq Biotechnology Index includes companies that are primarily engaged in using biomedical research for the discovery or development of novel treatments and cures for human disease (Boston Mass High Tech, MA)
